首页> 外文期刊>Pathology oncology research: POR >Open MR-guided high-dose-rate (HDR) prostate brachytherapy: feasibility and initial experiences open MR-guided high-dose-rate (HDR) prostate brachytherapy.
【24h】

Open MR-guided high-dose-rate (HDR) prostate brachytherapy: feasibility and initial experiences open MR-guided high-dose-rate (HDR) prostate brachytherapy.

机译:开放式MR指导高剂量率(HDR)前列腺近距离放射治疗:可行性和初步经验开放式MR指导高剂量率(HDR)前列腺近距离放射治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of our pilot study was to demonstrate the feasibility and dosimetric quality of MR-guided HDR prostate brachytherapy in a low-field 0.35T open MRI scanner and to present our initial clinical experiences. 16 patients with intermediate- to high-risk localized prostate cancer were treated with 46-60 Gy of external beam radiotherapy preceded and/or followed by an 8 Gy MR-guided HDR boost. For interventions an MR compatible custom-made system, coaxial needles and plastic catheters were used. Template reconstruction, trajectory planning, image guidance, contouring and treatment planning were exclusively based on MR images. For treatment planning, dose-point- and anatomy-based inverse planning optimization was used. Image quality was found to be good to excellent in almost all cases. The mean catheter placement accuracy modeled by Rayleigh distribution was 2.9 mm with a sigma value of 2.3 mm. The mean and standard deviation (SD) of the dosimetric results for the target volume were the following: V100: 94.2 +/- 4.3%, V150: 43.9 +/- 6.8%, V200: 18.5 +/- 5.9%. The mean D(0.1), D(1) and D1 values for the intraprostatic urethra were 117.6 +/- 12.5%, 98.5 +/- 19.9% and 122.3 +/- 16.4%, respectively. Regarding the rectal wall the mean D(0.1), D(1) and D(2) values were 77.3 +/- 7.2%, 64.8 +/- 7.5%, and 53.2 +/- 9.1%, respectively. The mean maximum dose for the inner rectal surface was 53.5 +/- 9.2%. No RTOG Grade 3 or worse acute toxicities were observed. Our method seems to be a promising approach for performing feasible, accurate and high-quality MR-guided HDR prostate brachytherapy. To determine the long term side effects and outcome higher number of patients, additional follow-up is needed.
机译:我们的初步研究的目的是证明在低场0.35T开放MRI扫描仪中MR引导的HDR前列腺近距离放射疗法的可行性和剂量学质量,并介绍我们的初步临床经验。在中和高危局限性前列腺癌患者中,对16例患者进行了46-60 Gy的体外束放射治疗,之后和/或之后进行了8 Gy MR引导的HDR增强治疗。为了进行干预,使用了MR兼容的定制系统,同轴针头和塑料导管。模板重建,轨迹计划,图像指导,轮廓绘制和治疗计划完全基于MR图像。对于治疗计划,使用了基于剂量点和解剖学的反向计划优化。发现在几乎所有情况下,图像质量都很好。由瑞利分布模型模拟的平均导管放置精度为2.9 mm,σ值为2.3 mm。目标体积剂量学结果的平均值和标准偏差(SD)如下:V100:94.2 +/- 4.3%,V150:43.9 +/- 6.8%,V200:18.5 +/- 5.9%。前列腺内尿道的平均D(0.1),D(1)和D1值分别为117.6 +/- 12.5%,98.5 +/- 19.9%和122.3 +/- 16.4%。对于直肠壁,平均D(0.1),D(1)和D(2)值分别为77.3 +/- 7.2%,64.8 +/- 7.5%和53.2 +/- 9.1%。直肠内表面的平均最大剂量为53.5 +/- 9.2%。没有观察到RTOG 3级或更严重的急性毒性。我们的方法似乎是进行可行,准确和高质量的MR引导的HDR前列腺近距离放射治疗的有前途的方法。为了确定长期副作用和更多患者的预后,还需要进一步的随访。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号